Skip to main content
. Author manuscript; available in PMC: 2016 Sep 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2015 Jun 17;287(3):240–245. doi: 10.1016/j.taap.2015.06.008

Fig. 3.

Fig. 3

Activations of p53 and p21 upon acute exposure of BEAS-2B cells to Cr(VI). A, p53 and p21 activity. BEAS-2B cells were transfected with either p53 or p21 luciferase report for overnight, followed by treatment with Cr(VI) at doses of 5 μM and 10 μM for 24 hr. The cells were harvested for luciferase assay. B, BEAS-2B cells were treated with 5 μM and 10 μM of Cr(VI) for 24 hr. RNA was isolated from the cells and subjected for RT-PCR analysis. C, BEAS-2B cells were treated with Cr(VI) for 24 hr and 48 hr. Whole cell lysate was prepared for immunoblotting. *, p<0.05 compared to control group without Cr(VI) treatment.